Pfizer inks collaboration deal to use CytoReason's cell-centered models of immune system

Microsoft has revamped its MMLSpark open source project (Image kamisoka / iStockPhoto)
CytoReason expects to receive payments from Pfizer that could reach into “low double-digit millions” of U.S. dollars. (kamisoka/iStockPhoto)

Pharma giant Pfizer has inked a deal with CytoReason to use the Tel Aviv-based drug discovery and development company’s cell-centered models of the immune system.

CytoReason’s machine learning technology can rebuild lost cellular information from gene expression data and associate genes to specific cells. In turn, that information is integrated with other data to create a cell-based model of the trial-specific immune response.

Although financial terms of the deal weren’t disclosed, CytoReason expects to receive payments from Pfizer that could reach into “low double-digit millions” of U.S. dollars.

CONFERENCE

AI Innovations for Life Science and Healthcare Summit East

Join the expert speaking faculty of over 30 life science, healthcare, and tech professionals on June 13–14, 2019, in Philadelphia, as we elevate clinical trial operations, healthcare outcomes, and supply chain implementation through AI. Use Discount Code 796819FIERCE to save 15% off the standard registration rate.

“This will be our fifth major partnership, which we believe will help make our model unparalleled in its accuracy for assets across the pipeline,” David Harel, CytoReason’s chief executive, said in a statement (PDF). “CytoReason’s model brings together thousands of samples on a cell-protein-gene level, allowing for fast and accurate insights.”

So far, the company has two pending patents, 10 commercial and scientific collaborations and 16 peer-reviewed publications. Its technology can target cancer immunotherapy, autoimmune, neurodegenerative and infectious diseases.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.